Drug Cocktail Boasts 97% Hepatitis C Cure Rate in Patients Coinfected with HIV
A novel hepatitis C treatment that combines sofosbuvir with another drug not yet approved in the US had a 97% success rate in a group of patients who were coinfected with HIV, according to a news release from the University of California, San Diego (UCSD) School of Medicine.
UCSD researchers assisted in the study conducted at 37 centers in the US and results were published in the New England Journal of Medicine. The treatment, which combined the FDA-approved drug sofosbuvir (Sovaldi) with daclatasvir, cured the hepatitis C virus (HCV) in 97% of patients who were also infected with HIV.
“These findings are very exciting in the infectious diseases world, as they could help an entire demographic that has historically struggled finally receive successful treatment for HCV,” lead author David Wyles, MD, said in the release.
Daclatasvir is an NS5A inhibitor currently under regulatory review in the US and sofosbuvir is a NS5B inhibitor. The two drugs combined have previously been shown to be effective in clinical trials with hepatitis C virus (HCV) monoinfection, according to the NEJM article.
Chronic infection of HCV can lead to serious liver damage, including cirrhosis, liver cancer and the need for a liver transplant. Liver disease is a leading cause of death among patients with human immunodeficiency virus type 1 (HIV-1).
Up to 30% of patients with hepatitis C are coinfected with HIV, according to the UCSD release. However, treatment options for HCV have been limited for many coinfected patients because of adverse drug interactions with the HIV medicine they take.
We Are Fossasia Stay Connected With Us On Twitter . . . ! ! !
A novel hepatitis C treatment that combines sofosbuvir with another drug not yet approved in the US had a 97% success rate in a group of patients who were coinfected with HIV, according to a news release from the University of California, San Diego (UCSD) School of Medicine.
UCSD researchers assisted in the study conducted at 37 centers in the US and results were published in the New England Journal of Medicine. The treatment, which combined the FDA-approved drug sofosbuvir (Sovaldi) with daclatasvir, cured the hepatitis C virus (HCV) in 97% of patients who were also infected with HIV.
“These findings are very exciting in the infectious diseases world, as they could help an entire demographic that has historically struggled finally receive successful treatment for HCV,” lead author David Wyles, MD, said in the release.
Daclatasvir is an NS5A inhibitor currently under regulatory review in the US and sofosbuvir is a NS5B inhibitor. The two drugs combined have previously been shown to be effective in clinical trials with hepatitis C virus (HCV) monoinfection, according to the NEJM article.
Chronic infection of HCV can lead to serious liver damage, including cirrhosis, liver cancer and the need for a liver transplant. Liver disease is a leading cause of death among patients with human immunodeficiency virus type 1 (HIV-1).
Up to 30% of patients with hepatitis C are coinfected with HIV, according to the UCSD release. However, treatment options for HCV have been limited for many coinfected patients because of adverse drug interactions with the HIV medicine they take.
We Are Fossasia Stay Connected With Us On Twitter . . . ! ! !
No comments:
Post a Comment